The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (Orgovyx), for adult patients with advanced prostate cancer. GnRH antagonists belong to a class of hormone therapy medications … Continue reading Oral Hormone Therapy for Advanced Prostate Cancer